文献速递静脉血栓栓塞慢性静脉疾病

专用静脉镍钛支架治疗慢性下腔静脉闭塞的结果

Results of dedicated venous nitinol stents in treating chronic inferior vena cava occlusions.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2025-12-29

本研究回顾性分析了22例因深静脉血栓或先天异常导致慢性下腔静脉闭塞的患者,采用专用静脉镍钛支架行腔内再通和支架置入。技术成功率为95%,12个月下腔静脉支架一期通畅率为100%,所有患者症状改善且静脉溃疡愈合。结论认为该治疗安全且中期通畅率良好。

要点

  • 专用静脉镍钛支架治疗慢性下腔静脉闭塞技术成功率高,12个月一期通畅率100%。
  • 术后所有患者症状改善,静脉溃疡在1年内愈合。
  • 30天内出血相关并发症发生率为9.5%,需关注抗凝管理。

核心结论

  • 使用专用静脉镍钛支架治疗慢性下腔静脉闭塞安全,术后1年中期通畅率优异且症状改善。

研究设计与样本

  • 单中心回顾性研究,纳入2022年至2025年接受腔内再通和镍钛静脉支架置入的22例患者。

主要发现

  • 技术成功21例(95%),中位随访259天,下腔静脉支架12个月一期通畅率100%。
  • 包括下腔静脉和髂股静脉支架在内的所有重建组件1年一期和二期通畅率分别为84%和100%。
  • 所有患者报告症状改善,术前存在的静脉溃疡在1年内愈合。
  • 30天内2例(9.5%)发生出血相关并发症。

关键数值与推荐

  • 中位年龄41岁(IQR 37-71),男性77%,活动性吸烟55%,高血压41%,高凝状态32%。
  • 91%患者有血栓后综合征,55%为CEAP 4-6级,27%有下腔静脉滤器闭塞。
  • 病因:深静脉血栓59%,滤器相关血栓18%,手术相关狭窄9%,先天异常9%,下腔静脉夹闭5%。
  • 支架近端位于肾下11例(52%),肾上10例(48%);股总静脉支架置入27条肢体(64%)。
  • 锐性再通3例(14%),术后均抗凝,中位住院1天(IQR 0-2)。

临床怎么用

  • 对于有症状的慢性下腔静脉闭塞,可考虑使用专用静脉镍钛支架行腔内再通和支架置入。
  • 术后需抗凝并监测出血并发症,尤其是30天内。
  • 该技术可改善症状并促进静脉溃疡愈合,但需多中心大样本研究进一步验证。

局限性

  • 单中心回顾性研究,样本量小(22例),随访时间有限(中位259天)。
  • 缺乏标准化结局指标如生活质量和成本测量。
  • 需要多机构更大样本研究验证 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Inferior vena cava (IVC) occlusion resulting from deep vein thrombosis (DVT) or embryologic developmental abnormalities can result in debilitating symptoms, including lower extremity pain, edema, and venous ulceration. This study describes the outcomes associated with endovascular recanalization and stenting of chronic IVC occlusions with dedicated venous nitinol stents. METHODS: Patients who underwent endovascular recanalization and nitinol venous stenting at a single institution from 2022 to 2025 were identified. Demographics, comorbidities, CEAP classification, venous reconstruction details, and outcomes, including symptomatic improvement and 30-day complications, were collected. Descriptive analysis was completed. Primary and secondary patency was assessed using Kaplan-Meier analysis. RESULTS: A total of 22 patients with symptomatic IVC occlusions underwent attempted recanalization. The median age at the time of treatment was 41 years (interquartile range [IQR], 37-71 years), and patients were predominantly male (77%). Patient comorbidities included active tobacco use (55%), hypertension (41%), and hypercoagulable disorders (32%). On presentation, 20 patients (91%) had post-thrombotic syndrome, 12 (55%) had CEAP class 4 to 6 chronic venous disease, six (27%) had occluded IVC filters, four (18%) had a prior failed venous intervention, and five (23%) had chronic stent occlusions. The etiology of chronic IVC occlusion included DVT in 13 patients (59%), IVC filter-associated thrombosis in four patients (18%), surgical-related IVC stenosis in two patients (9%), congenital abnormalities in two patients (9%), and IVC clipping in one patient (5%). Cranial extent of stenting was infrarenal in 11 patients (52%) and suprarenal in 10 patients (48%). Common femoral veins were stented in 27 patients (64% of limbs). Sharp recanalization was required in three patients (14%). A total of 21 patients (95%) achieved technical success. All patients were anticoagulated postoperatively, and the median length of stay was 1 day (IQR, 0-2 days). Two patients (9.5%) experienced bleeding-related complications within 30 days. The median follow-up was 259 days (IQR, 78-473 days). Primary patency for the IVC stents was 100% at 12 months. Primary and secondary patency for all components within the venous reconstruction, including IVC and iliofemoral stents, was 84% and 100% at 1 year, respectively. All patients reported symptomatic improvement and venous ulcers healing (if present at index presentation) within 1 year following intervention. CONCLUSIONS: Treatment of chronic IVC occlusions using dedicated venous nitinol stents is safe with excellent midterm patency and symptom improvement at 1 year postoperatively. Multi-institutional studies with larger patient populations and standardized outcomes, including quality of life and cost measures, are required to further validate the study findings.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Wang KM, Murphy BE, Hemingway JF, et al. Results of dedicated venous nitinol stents in treating chronic inferior vena cava occlusions. J Vasc Surg Venous Lymphat Disord. 2025. PMID: 41475613. doi:10.1016/j.jvsv.2025.102440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。